Riley Antony A, CFO, reported an open-market or private purchase at Forte Biosciences, Inc. involving 9680.000000 shares for an estimated $254832.78. Reported holdings after the transaction were 41520.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.
Form 4 relationship flags and nearby filing context
CHIEF FINANCIAL OFFICER
Represents the weighted average share price of an aggregate total of 9,680 shares purchased in the price range of $26.2243 to $26.59 by the reporting person. The reporting person undertakes to provide…
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
On January 1, 2026, the Reporting Person's RSUs vested. The closing price of the Issuer's Common Stock on December 31, 2025 was the settlement price used to calculate the shares withheld.
Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to t…
0 other filings
0 recent txs